Targeted Oncology2h
FDA Approves Cologuard Plus Stool DNA Test for Colorectal Cancer Screening
The noninvasive test provides a beneficial screening tool for patients 45 and older at average risk for colorectal cancer.
The American Journal of Managed Care6h
Nivolumab Approved as Neoadjuvant, Adjuvant Therapy for NSCLC by FDA
The approval came days before the FDA’s expected deadline and makes this the only PD-1 inhibitor approved for resectable ...
Cancer Therapy Advisor7h
Opdivo Approved in Neoadjuvant and Adjuvant Setting for Resectable NSCLC
The FDA has approved Opdivo (nivolumab) as neoadjuvant and adjuvant treatment for adults with resectable NSCLC.
Bristol Myers' $10B Cancer Drug Opdivo Scores Expanded Use FDA Approval For Lung Cancer In Pre And Post-Surgery Setting
Opdivo (nivolumab) for resectable non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor (EGFR) ...
pharmaphorum10h
FDA approval give BMS an edge in NSCLC treatment
In 2023, BMS received a similar approval across the pond. The National Institute for Health and Care Excellence (NICE) cleared Opdivo (nivolumab) for use with platinum-based chemo to reduce the size ...